Rosen Law Firm Reminds Hemispherx Biopharma Investors of Important February 22, 2013 Deadline -- HEB

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130216:nGNXUXENBa

NEW YORK, Feb. 16, 2013 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds investors of the important
February 22, 2013 lead plaintiff deadline in the class action filed on behalf of investors who
purchased the securities of Hemispherx Biopharma, Inc. (NYSE:HEB) from March 19, 2012 through
December 17, 2012.

To join the Hemispherx class action, visit the firm's website at http://rosenlegal.com
http://www.globenewswire.com/newsroom/ctr?d=10022066&l=2&a=http%3A%2F%2Frosenlegal.com&u=http%3A%2F%2Frosenlegal.com%2F
, or call Phillip Kim, Esq., toll-free, at 866-767-3653; you may also email pkim@rosenlegal.com
http://www.globenewswire.com/newsroom/ctr?d=10022066&l=2&a=pkim%40rosenlegal.com&u=mailto%3Apkim%40rosenlegal.com
for information on the class action.

The Complaint asserts violations of the federal securities laws against Hemispherx and its
officers and directors for issuing false and misleading information about its lead drug candidate
Ampligen. Specifically, that Hemispherx misstated the safety and efficacy of Ampligen, and touted
purportedly positive results from Ampligen's clinical trials.

On December 18, 2012, the FDA published a staff report concluding that the Company's studies were
"ill-defined and invalid" with signals of efficacy that were inconsistent between clinical trials,
and based on the limited quality of the data, "it is difficult to draw conclusions regarding
potential safety signals," but the "review identified nine potential safety concerns associated
with Ampligen." The Complaint alleges that as a result of this adverse information, Hemispherx
stock price dropped and investors have been damaged.

If you wish to serve as lead plaintiff, you must move the Court no later than February 22, 2013.
A lead plaintiff is a representative party acting on behalf of other class members in directing
the litigation. If you wish to join the litigation, or to discuss your rights or interests
regarding this class action, please contact Phillip Kim, Esq. of The Rosen Law Firm, toll-free, at
866-767-3653, or via e-mail at pkim@rosenlegal.com
http://www.globenewswire.com/newsroom/ctr?d=10022066&l=5&a=pkim%40rosenlegal.com&u=mailto%3Apkim%40rosenlegal.com
. You may also visit the firm's website at http://rosenlegal.com
http://www.globenewswire.com/newsroom/ctr?d=10022066&l=5&a=http%3A%2F%2Frosenlegal.com&u=http%3A%2F%2Frosenlegal.com%2F
.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in
securities class actions and shareholder derivative litigation.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT: Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm P.A.
275 Madison Avenue 34th Floor
New York, New York 10016
Tel: (212) 686-1060
Weekends Tel: (917) 562-8616
Toll Free: 1-866-767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
www.rosenlegal.com